Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.
Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR. Reese JM, et al. Among authors: negron v. BMC Cancer. 2014 Oct 7;14:749. doi: 10.1186/1471-2407-14-749. BMC Cancer. 2014. PMID: 25288324 Free PMC article.
ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis.
Reese JM, Bruinsma ES, Nelson AW, Chernukhin I, Carroll JS, Li Y, Subramaniam M, Suman VJ, Negron V, Monroe DG, Ingle JN, Goetz MP, Hawse JR. Reese JM, et al. Among authors: negron v. Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9580-E9589. doi: 10.1073/pnas.1807751115. Epub 2018 Sep 26. Proc Natl Acad Sci U S A. 2018. PMID: 30257941 Free PMC article.
Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Visscher DW, Goetz MP. Leon-Ferre RA, et al. Among authors: negron v. Breast Cancer Res Treat. 2018 Jan;167(1):89-99. doi: 10.1007/s10549-017-4499-7. Epub 2017 Sep 14. Breast Cancer Res Treat. 2018. PMID: 28913760 Free PMC article.
Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues.
Hawse JR, Carter JM, Aspros KGM, Bruinsma ES, Koepplin JW, Negron V, Subramaniam M, Ingle JN, Rech KL, Goetz MP. Hawse JR, et al. Among authors: negron v. Breast Cancer Res Treat. 2020 Jan;179(1):241-249. doi: 10.1007/s10549-019-05441-3. Epub 2019 Sep 30. Breast Cancer Res Treat. 2020. PMID: 31571071 Free PMC article.
A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.
Polley MC, Leon-Ferre RA, Leung S, Cheng A, Gao D, Sinnwell J, Liu H, Hillman DW, Eyman-Casey A, Gilbert JA, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari K, Couch F, Carter JM, Visscher DW, Nielsen TO, Goetz MP. Polley MC, et al. Among authors: negron v. Breast Cancer Res Treat. 2021 Feb;185(3):557-566. doi: 10.1007/s10549-020-06030-5. Epub 2021 Jan 3. Breast Cancer Res Treat. 2021. PMID: 33389409 Free PMC article. Review.
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.
Reinholz MM, Zinnen SP, Dueck AC, Dingli D, Reinholz GG, Jonart LA, Kitzmann KA, Bruzek AK, Negron V, Abdalla AK, Arendt BK, Croatt AJ, Sanchez-Perez L, Sebesta DP, Lönnberg H, Yoneda T, Nath KA, Jelinek DF, Russell SJ, Ingle JN, Spelsberg TC, Dixon HB, Karpeisky A, Lingle WL. Reinholz MM, et al. Among authors: negron v. Bone. 2010 Jul;47(1):12-22. doi: 10.1016/j.bone.2010.03.006. Epub 2010 Mar 15. Bone. 2010. PMID: 20233612 Free PMC article.
34 results